ABM1 Antibody

What is ABM1 and how does it function in immune response pathways?

ABM1 is a STING (Stimulator of Interferon Genes) agonist-based molecule designed to enhance immune responses. It belongs to the SABER family of compounds that target the endoplasmic reticulum and boost antigen cross-presentation. Similar to other compounds in this class, ABM1 likely functions by activating the STING pathway, which leads to phosphorylation of STING and TBK1 (TANK-binding kinase 1), ultimately triggering downstream immune signaling cascades .

The mechanism involves stimulation of dendritic cells, particularly bone marrow-derived dendritic cells (BMDCs), where the efficacy can be measured through half-maximal effective concentration (EC50) values. The activation of STING is crucial for the compound's function, as demonstrated in studies using STING-deficient BMDCs, where related compounds showed no activity .

How does ABM1 compare structurally and functionally with other SABER compounds?

ABM1 belongs to a family of SABER compounds that includes derivatives such as ABN1, ABN2, and ABM5. While comprehensive comparative data specifically for ABM1 is limited in the available literature, insights can be gained from studies on related compounds:

Both ABN1 and ABN2 were synthesized with an azide group, enabling conjugation with various unnatural amino acids, while maintaining potency comparable to diABZI (a reference STING agonist) . The functional similarities across these compounds suggest a conserved mechanism of action despite structural variations.

What experimental evidence supports ABM1's role in immune modulation?

While direct experimental evidence specifically for ABM1 is somewhat limited in the provided literature, research on related SABER compounds provides valuable insights. For instance, ABM5-conjugated peptides demonstrated significant ability to promote cross-presentation of antigens like ovalbumin (OVA) epitopes. The efficacy of these compounds depends entirely on STING, as confirmed through experiments with STING^(−/−) BMDCs where no activation was observed .

The experimental support for the SABER family's immune modulatory effects includes:

• Demonstration of STING and TBK1 phosphorylation following administration

• Verification of efficacy using knockout models (STING^(−/−))

• Measurement of antigen presentation via MHC-I complexes

• Assessment of downstream immune responses, including antibody production and T cell activation

What protocols are recommended for evaluating ABM1 efficacy in dendritic cells?

Based on methodologies applied to related SABER compounds, researchers investigating ABM1 should consider the following protocol elements:

• Cell Preparation: Isolate bone marrow-derived dendritic cells (BMDCs) using standard protocols. For more comprehensive analysis, FLT3L-induced BMDCs can be used to study effects on different dendritic cell subsets including conventional dendritic cells type 1 (cDC1s) and type 2 (cDC2s) .

• Dosage Determination: Establish the half-maximal effective concentration (EC50) through dose-response experiments. This typically involves treating BMDCs with varying concentrations of ABM1 and measuring activation markers .

• Activation Assessment: Evaluate STING pathway activation by measuring phosphorylation of STING and TBK1 through western blotting. Include appropriate time points (e.g., 0.5, 1, 2, 4, 8, and 24 hours post-treatment) to capture both early and sustained activation .

• Flow Cytometry Analysis: Identify activated dendritic cell populations using markers including CD11c, CD24, CD86, B220, CD172α, and MHC-I presentation of relevant peptides (e.g., H2-K^b-SIINFEKL for OVA studies) .

• Controls: Include both positive controls (e.g., diABZI) and negative controls (untreated cells and STING^(−/−) cells) to validate specificity of the response .

How can ABM1 be incorporated into antigen cross-presentation studies?

To incorporate ABM1 into cross-presentation studies, researchers should consider the following approach based on methodologies used with related compounds:

• Conjugation Strategy: Conjugate ABM1 to peptide antigens containing appropriate binding sites. For example, if ABM1 contains a maleimide group (like ABM5), it can be conjugated to peptides with an N-terminal cysteine, forming a stable coupling through cyclization .

• Antigen Selection: Choose model antigens with well-characterized MHC-I epitopes, such as ovalbumin (OVA) and specifically the SIINFEKL epitope (OVA257–264). Consider using longer peptides (e.g., OVA250–264) that require further processing, simulating clinical scenarios with tumor neoantigens .

• Verification of Conjugation: Confirm successful conjugation through high-performance liquid chromatography and mass spectrometry before proceeding with functional assays .

• Functional Assessment: Evaluate the ability of ABM1-conjugated antigens to:

  • Activate dendritic cells (measure EC50)

  • Induce phosphorylation of STING and TBK1

  • Promote cross-presentation of the conjugated epitope (measure via flow cytometry using epitope-specific antibodies, e.g., anti-H2-K^b-SIINFEKL)

• In Vivo Validation: Assess cross-presentation in lymphoid tissues after subcutaneous injection of the conjugates, analyzing draining lymph nodes for activated dendritic cell subsets and antigen presentation .

What flow cytometry markers are most relevant for studying ABM1 effects on dendritic cell populations?

When analyzing dendritic cell populations and their response to ABM1 treatment, the following markers have proven valuable in studies with related compounds:

For comprehensive analysis, researchers should incorporate Live/Dead staining (1:400 dilution) to exclude non-viable cells from the analysis . This panel allows distinction between dendritic cell subsets with different functional specializations and direct measurement of antigen cross-presentation.

What conjugation techniques are optimal for linking ABM1 to peptide antigens?

Optimal conjugation techniques for ABM1 would depend on its specific chemical structure. Based on studies with related compounds, the following approaches have proven effective:

• Maleimide-Cysteine Chemistry: If ABM1 contains a maleimide group (like ABM5), it can be efficiently conjugated to peptides with an N-terminal cysteine. This reaction forms a stable thioether bond that further cyclizes, creating a more stable coupling. This approach has been successfully used with model antigens such as OVA peptides .

• Click Chemistry: For ABM1 derivatives containing azide groups (similar to ABN1 and ABN2), copper-catalyzed azide-alkyne cycloaddition (CuAAC) can be employed. This approach enables conjugation with peptides containing unnatural amino acids with alkyne groups .

• Adaptation to Epitope Characteristics: The choice between conjugation strategies should consider the presence of reactive amino acids within the epitope sequence. For example, when working with the neoantigen M27 that contains cysteine, researchers switched from an ABM5-based approach to ABN2 to avoid unwanted side reactions .

After conjugation, verification through analytical techniques such as high-performance liquid chromatography and mass spectrometry is essential to confirm product identity and purity before proceeding with biological experiments .

How do ABM1-conjugated antigens compare with traditional adjuvant approaches?

While direct comparisons specifically for ABM1 are not extensively documented in the provided literature, insights from related SABER compounds suggest several advantages over traditional adjuvants:

• Enhanced Cross-Presentation: SABER-conjugated peptides (like ABM5-OVA) demonstrate superior ability to promote antigen cross-presentation compared to unconjugated peptides with separate adjuvants like diABZI .

• Potent Antibody Induction: When used as adjuvants for protein antigens, SABER compounds like ABM5-SNT (where SNT appears to be a peptide conjugate) significantly enhance antibody responses in both primary and booster immunizations. In some contexts, they exhibit comparable or superior adjuvant effects to established adjuvants like diABZI, poly-I:C, and ISCOMs .

• Cross-Reactive Antibody Induction: In studies with SARS-CoV-2 RBD-Fc (a receptor binding domain subunit vaccine), ABM5-SNT demonstrated remarkable adjuvant effects, boosting cross-neutralizing antibodies against wild-type virus by over tenfold, while also inducing some cross-reactive antibodies against variants like BA.1 and BA.5 .

• Dual Immune Activation: Beyond humoral responses, these compounds also enhance T helper 1 CD4+ T cell responses, effectively mobilizing both cellular and humoral arms of the immune system .

What troubleshooting strategies should be employed when ABM1-based experiments yield inconsistent results?

Based on methodological details from related compound studies, researchers encountering inconsistent results with ABM1 should consider these troubleshooting approaches:

• STING Dependency Verification: Since SABER compounds depend entirely on STING for activity, verify STING expression and functionality in your experimental system. Consider including STING^(−/−) controls to confirm specificity .

• Conjugation Confirmation: Inconsistent conjugation efficiency can lead to variable results. Verify successful conjugation through analytical techniques before each experiment, and consider batch-testing conjugates for biological activity .

• Stability Assessment: Monitor the stability of ABM1 conjugates over time and under experimental conditions. The cyclization of maleimide-cysteine conjugates increases stability, but storage conditions may still affect activity .

• Dosage Optimization: Re-evaluate the EC50 of your specific ABM1 conjugate, as conjugation to peptides can slightly impair STING activation potency compared to the unconjugated compound .

• Cell Type Considerations: Different dendritic cell subsets may respond differently to stimulation. For cross-presentation studies, ensure sufficient representation of cDC1s, which specialize in this process .

• Kinetics Adjustment: SABER-peptide conjugates may exhibit different activation kinetics compared to unconjugated STING agonists, with slower but more persistent phosphorylation of STING and TBK1. Adjust time points in your assays accordingly .

How can ABM1 enhance antibody development and characterization studies?

ABM1 and related SABER compounds show significant potential for enhancing antibody development in several ways:

• Adjuvant Activity: When co-administered with protein antigens, SABER compounds can significantly boost antibody responses in both primary and booster immunizations, potentially improving the yield and quality of antibodies for research applications .

• Enhanced Epitope Recognition: By promoting more effective antigen presentation, ABM1 could potentially enhance the diversity of epitopes recognized by antibodies, potentially increasing the chances of generating functionally relevant antibodies .

• Cross-Reactive Antibody Generation: In vaccine studies, SABER compounds demonstrated the ability to enhance cross-reactive neutralizing antibody responses, suggesting potential applications in developing broadly neutralizing antibodies against variable pathogens .

• Improved Affinity Maturation: The enhanced CD4+ T helper cell responses promoted by SABER compounds may support more effective affinity maturation of antibody responses, potentially yielding higher-affinity antibodies .

For antibody characterization, researchers should consider techniques similar to those used for analyzing therapeutic antibodies, including binding assays (like ELISA), functional assessments, and structural analyses through computational approaches as described in the literature on therapeutic antibody design .

What considerations are important when using ABM1 in combination with immune checkpoint inhibitors?

The combination of ABM1-conjugated antigens with immune checkpoint inhibitors represents a promising approach for enhanced immunotherapy, particularly in challenging tumor models. Based on studies with related compounds, researchers should consider:

• Timing of Administration: In tumor models like B16F10, treatment initiation at appropriate time points (e.g., 6 days post-tumor inoculation) is critical for observing therapeutic benefits of the combination .

• Synergistic Potential: ABN2-conjugated neoantigen peptides (M27) combined with anti-PD1 demonstrated superior efficacy compared to all other treatment groups in B16F10 models, including the combination of poly-I:C + M27 + anti-PD1, highlighting the synergistic potential .

• Standalone Activity Assessment: Before combining with checkpoint inhibitors, evaluate the activity of ABM1-conjugated antigens alone, as they may exhibit significant anti-tumor effects compared to conventional approaches (e.g., diABZI + peptide) .

• Immune Cell Monitoring: During combination therapy, monitor changes in tumor-infiltrating lymphocytes and peripheral immune populations to understand the mechanistic basis of any enhanced effects .

• Resistance Models: Consider testing the combination approach in models known to be resistant to immune checkpoint therapy, such as B16F10, where SABER-based approaches have shown promise in overcoming resistance .

What are the methodological considerations for incorporating ABM1 into vaccine development research?

Researchers looking to incorporate ABM1 into vaccine development should consider these methodological approaches:

• Antigen Selection and Conjugation:

  • For neoantigen vaccines, select appropriate MHC-I epitopes and determine the optimal conjugation chemistry based on the epitope sequence

  • For subunit vaccines, consider co-administration of ABM1-peptide conjugates with the protein antigen rather than direct conjugation

• Delivery Systems:

  • Lipid nanoparticle (LNP) encapsulation has been successfully used with related compounds for in vivo delivery

  • Subcutaneous administration (10 nmol of LNP-encapsulated conjugate) effectively delivers the compounds to draining lymph nodes

• Immune Response Assessment:

  • Evaluate both cellular immunity (CD8+ T cell responses, cross-presentation) and humoral immunity (antibody titers, neutralizing activity)

  • For viral vaccines, assess cross-neutralization against variant strains using appropriate neutralization assays

• Prime-Boost Strategies:

  • While a single dose of RBD-Fc + ABM5-SNT was sufficient to induce high titers of specific antibodies, a second dose further boosted responses

  • Determine optimal intervals between prime and boost immunizations

• Cross-Protection Analysis:

  • For pathogens with variants (like SARS-CoV-2), assess cross-reactivity against multiple strains

  • Consider combining SABER-peptide vaccines targeting conserved T cell epitopes with subunit vaccines to induce both cellular and humoral cross-protection

How might computational approaches enhance ABM1 development and application?

Computational approaches could significantly advance ABM1 research through several avenues:

• Structure-Activity Relationship Modeling: Applying computational techniques to understand the relationship between structural modifications of ABM1 and its biological activity could guide the development of optimized derivatives with enhanced properties .

• Epitope Selection for Conjugation: Computational methods for epitope prediction and analysis could identify optimal epitopes for conjugation with ABM1, particularly for neoantigen vaccine development. These approaches might include:

  • Homology modeling to predict epitope structures

  • Docking simulations to understand ABM1-epitope interactions

  • Interface prediction to identify key binding residues

• Antibody Response Prediction: Computational tools could potentially predict the diversity and quality of antibody responses induced by ABM1-adjuvanted vaccines, helping to optimize formulations before experimental testing .

• Molecular Dynamics Simulations: These could provide insights into how ABM1 interacts with STING and how conjugation affects its conformational dynamics and activity .

The integration of these computational approaches with experimental validation represents a promising direction for optimizing ABM1-based immunotherapeutic strategies, following the trend of increasing computational contributions to therapeutic development .

What emerging research areas might benefit from ABM1 technology?

Based on the properties demonstrated by SABER compounds, several emerging research areas could benefit from ABM1 technology:

• Personalized Cancer Vaccines: The ability to conjugate ABM1 to neoantigen peptides makes it particularly suitable for developing personalized cancer vaccines targeting patient-specific mutations .

• Rapid Response Vaccine Platforms: The adaptability of the SABER platform to different peptide antigens could enable rapid development of vaccines against emerging pathogens or variants .

• Combination Immunotherapies: Beyond checkpoint inhibitors, exploring combinations with other immunomodulatory agents could yield novel therapeutic approaches for resistant cancers .

• Autoimmune Disease Research: The precise control of immune responses enabled by ABM1-conjugated antigens might be leveraged to study and potentially treat autoimmune conditions through targeted immunomodulation.

• Next-Generation Antibody Discovery: The enhanced antibody responses and cross-reactivity induced by ABM1 adjuvantation could facilitate the discovery of broadly neutralizing antibodies against challenging pathogens .

The versatility of the ABM1 platform positions it as a valuable tool across these diverse research areas, particularly where precise control of antigen presentation and immune activation is desired.